Natco Pharma's Hyderabad API facility receives EIR from US FDA
Natco Pharma Limited has announced successful closure of inspection with the receipt of an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for the inspection conducted at its Active Pharmaceutical Ingredient (API) facility in Mekaguda Village, near Hyderabad.
The inspection was conducted during the period August 5-9, 2019, the company said.
The inspection was conducted during the period August 5-9, 2019, the company said.
Comments
Post a Comment